Hatch-Waxman and BPCIA Cases and Trends to Watch in 2021 [IPWatchdog]

Blake Coblentz and Aaron Lukas co-authored an article about two major cases in 2021 that could have long-lasting effects on where and how Hatch-Waxman and Biologics Price Competition and Innovation Act (BPCIA) cases are litigated. Specifically, the future of skinny labels is in doubt, and available venues for plaintiffs could be significantly narrowed. The number of new drugs eligible for generic competition will also rebound in 2021, but only time will tell if the global pandemic affects the overall number of generic filings. While there are many more Hatch-Waxman and BPCIA developments to watch this year, these are a few that we will be following closely.

To read more of this article, click here.

Share Page On LinkedIn

Related Attorneys

W. Blake Coblentz

Co-Chair, Hatch-Waxman & Biologics
Vice Chair, Intellectual Property


(202) 912-4837

Aaron Lukas, Ph.D.

Co-Chair, Hatch-Waxman & Biologics


(202) 912-4823

Related Practices